← Leaderboards
Diane M Puccetti
University Of Wisconsin Madison
$719,707
Attributed
$719,707
Total exposure
5
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$719,707 · 5
By mechanism
M01$719,707 · 5
Top collaborators
No co-investigators on record.
Most similar at University Of Wisconsin Madison
Same institution · by research overlap
- Joan H Schiller$7,395,575
- Janet E Mertz$9,069,554
- Yousif H Matloub$547,398
- William Franklin Dove$12,247,712
- Glen S Kwon$5,558,269
Others in their field
Top investigators on “Child (0-11)”
- Stephen A Spector · University Of California, San Diego$19,469,014
- Gregory H Reaman · National Childhood Cancer Foundation$18,799,431
- Stephen J Durako · Westat, Inc.$15,048,684
- Robert J Adams · Medical College Of Georgia (Mcg)$13,030,708
- Andrew J Cherlin · Johns Hopkins University$13,025,834
- Fernando D Martinez · University Of Arizona$12,692,039
Research focus
Child (0-11)Human SubjectNeoplasm /Cancer ChemotherapyClinical ResearchCombination ChemotherapyDrug Screening /EvaluationHuman Therapy EvaluationOral AdministrationMethotrexateAntineoplasticsAcute Lymphocytic LeukemiaCortisolVincristineAdolescence (12-20)Cis Platinum CompoundCognitionCyclophosphamideHodgkin'S DiseaseHuman MorbidityHuman MortalityLomustineMedulloblastomaNeoplasm /Cancer Radiation TherapyNeoplasm /Cancer Relapse /Recurrence
Grant awards (18)
Oral MP vs. Oral TG and IT MTX vs. IT MTX/Cytarabine/Hydrocortisone for SR-ALL$41,542
M01 · FY2004 · RR
PHASE III K XRT FOLLOWED BY ONE OF TWO ADJUVANT CHEMOTHERAPY REGIMENS$106,600
M01 · FY2002 · RR
ORAL MP VS ORAL TG &IT MTX VS IT MTX &CYTARABINE &HYDROCORTISONE F$106,600
M01 · FY2002 · RR
COMPREHENSIVE STUDY OF CLINICALLY STAGED PEDIATRIC HODGKINS DISEASE$106,600
M01 · FY2002 · RR
ORAL MP VS ORAL TG &IT MTX VS IT MTX &CYTARABINE &HYDROCORTISONE F$106,600
M01 · FY2001 · RR
PHASE III K XRT FOLLOWED BY ONE OF TWO ADJUVANT CHEMOTHERAPY REGIMENS$106,600
M01 · FY2001 · RR
COMPREHENSIVE STUDY OF CLINICALLY STAGED PEDIATRIC HODGKINS DISEASE$106,600
M01 · FY2001 · RR
COMPREHENSIVE STUDY OF CLINICALLY STAGED PEDIATRIC HODGKINS DISEASE$12,855
M01 · FY2001 · RR
ORAL MP VS ORAL TG &IT MTX VS IT MTX &CYTARABINE &HYDROCORTISONE F$12,855
M01 · FY2001 · RR
PHASE III K XRT FOLLOWED BY ONE OF TWO ADJUVANT CHEMOTHERAPY REGIMENS$12,855
M01 · FY2001 · RR
ORAL MP VS ORAL TG &IT MTX VS IT MTX &CYTARABINE &HYDROCORTISONE F$0
M01 · FY2000 · RR
DOCETAXEL (TAXOTERE) IN CHILDREN WITH RECURRENT SOLID TUMORS$0
M01 · FY2000 · RR
COMPREHENSIVE STUDY OF CLINICALLY STAGED PEDIATRIC HODGKINS DISEASE$0
M01 · FY2000 · RR
PHASE III K XRT FOLLOWED BY ONE OF TWO ADJUVANT CHEMOTHERAPY REGIMENS$0
M01 · FY2000 · RR
PHASE III K XRT FOLLOWED BY ONE OF TWO ADJUVANT CHEMOTHERAPY REGIMENS$0
M01 · FY2000 · RR
ORAL MP VS ORAL TG &IT MTX VS IT MTX &CYTARABINE &HYDROCORTISONE F$0
M01 · FY2000 · RR
DOCETAXEL (TAXOTERE) IN CHILDREN WITH RECURRENT SOLID TUMORS$0
M01 · FY2000 · RR
COMPREHENSIVE STUDY OF CLINICALLY STAGED PEDIATRIC HODGKINS DISEASE$0
M01 · FY2000 · RR